CJC-1295 (with DAC) / Ipamorelin
Each month we spotlight one compound from our research catalog. This month, it’s CJC-1295 with DAC paired with Ipamorelin, two peptides researchers often study side by side.
CJC-1295 with DAC is a long-acting analog of growth hormone–releasing hormone (GHRH). Its Drug Affinity Complex binds albumin, which extends its half-life in research models. Ipamorelin is a selective ghrelin-receptor agonist. In lab and cell models, researchers look at how the two act on separate signaling pathways, and at how the pairing shapes the timing and pattern of growth hormone release.
Our CJC-1295 (with DAC) / Ipamorelin Pen comes ready-to-use for consistent lab work. Store it at 36–46°F. COA available upon request, and free shipping on orders over $200. Looking for the short-acting version? See the CJC-1295 (No DAC) / Ipamorelin Pen. For background studies, visit the CJC/Ipamorelin research page.
Latest Research Studies
Selected peer-reviewed references for laboratory research context, newest first. Links open PubMed records. No combination study of CJC-1295 with ipamorelin has been published; the studies below cover each compound separately.
CJC-1295 (with DAC)
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ (2009). Growth Horm IGF Res. PubMed 19386527
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog Ionescu M, Frohman LA (2006). J Clin Endocrinol Metab. PubMed 17018654
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse Alba M, Fintini D, Sagazio A, et al. (2006). Am J Physiol Endocrinol Metab. PubMed 16822960
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Teichman SL, Neale A, Lawrence B, et al. (2006). J Clin Endocrinol Metab. PubMed 16352683
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Jetté L, Léger R, Thibaudeau K, et al. (2005). Endocrinology. PubMed 15817669
Ipamorelin
- Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus Beck DE, Sweeney WB, McCarter MD (2014). Int J Colorectal Dis. PubMed 25331030
- Efficacy of ipamorelin, a novel ghrelin agonist, in a rodent model of postoperative ileus Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B (2009). J Pharmacol Exp Ther. PubMed 19289567
- Influence of chronic treatment with the growth hormone secretagogue ipamorelin, in young female rats: somatotroph response in vitro Jiménez-Reina L, Cañete R, de la Torre MJ, et al. (2002). Histol Histopathol. PubMed 12168778
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers Gobburu JV, Agersø H, Jusko WJ, Ynddal L (1999). Pharm Res. PubMed 10496658
- Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats Johansen PB, Nowak J, Skjaerbaek C, et al. (1999). Growth Horm IGF Res. PubMed 10373343
- Ipamorelin, the first selective growth hormone secretagogue Raun K, Hansen BS, Johansen NL, et al. (1998). Eur J Endocrinol. PubMed 9849822
Research use only.